NAMSNewAmsterdam Pharma Company N.V.
What is the market doing?
The market is leaning against it: in a downtrend (−30% vs 200-day) and heavily shorted (+13% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −30% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How NAMS is trading
NewAmsterdam Pharma Company N.V. is −19% over the past year while the S&P 500 is +18%: 37 points behind the market. Through the fall, its own insiders bought $186K more stock than they sold.
1-year return · S&P 500 +18%
- vs 200-day average
- −30%
vs 200-day average · a clear downtrend
- RSI (14)
- 42
RSI (14) · neutral
- Below its 52-week high
- 48%
Below its 52-week high
Details›
- Last close2026-10-09
- $21.58
- 1 monthS&P 500 +2.7%
- −1.3%
- 1 yearS&P 500 +18%
- −19%
- 5 yearsS&P 500 +88%
- +119%
- vs 50-day average$25.03
- −14%
- 52-week high
- $41.45
- 52-week low
- $21.14
- Annualised volatility
- 64%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $186K
| Year | Return |
|---|---|
| 2026 (year to date) | −38% |
| 2025 | +36% |
| 2024 | +130% |
| 2023 | +2.5% |
| 2022 | +12% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 3 of 5 | +16% |
| Feb | 5 | 2 of 5 | +3.7% |
| Mar | 6 | 3 of 6 | −1.7% |
| Apr | 6 | 2 of 6 | −2.9% |
| May | 6 | 1 of 6 | −1.1% |
| Jun | 6 | 3 of 6 | −2.8% |
| Jul | 6 | 2 of 6 | −0.97% |
| Aug | 6 | 2 of 6 | −2.3% |
| Sep | 6 | 4 of 6 | +1.2% |
| Oct | 6 | 3 of 6 | +3.7% |
| Nov | 5 | 3 of 5 | +2.9% |
| Dec | 5 | 3 of 5 | +13% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.